Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | KITE-753 |
| Trade Name | |
| Synonyms | KITE753|KITE 753 |
| Drug Descriptions |
KITE-753 comprises autologous T-lymphocytes manufactured to preserve juvenile T-cells and engineered to express a chimeric antigen receptor (CAR) targeting CD19 containing a CD28 co-stimulatory domain and a CAR targeting CD20 with a 4-1BB co-stimulatory domain, which potentially decrease tumor growth (Blood (2025) 146 (Supplement 1): 704). |
| DrugClasses | CD19 Immune Cell Therapy 74 CD20 Immune Cell Therapy 16 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| KITE-753 | KITE-753 | 0 | 1 |